These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Pharmacological treatment of multiple sclerosis]. Myhr KM. Tidsskr Nor Laegeforen; 2010 Mar 11; 130(5):490-2. PubMed ID: 20224616 [Abstract] [Full Text] [Related]
3. Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis. Banwell B, Tremlett H. Neurology; 2005 Mar 08; 64(5):778-9. PubMed ID: 15753408 [No Abstract] [Full Text] [Related]
4. Editorial: the pitfalls of combination therapy. Vermersch P. Int MS J; 2006 Nov 08; 13(3):75-6. PubMed ID: 17101074 [No Abstract] [Full Text] [Related]
5. Use of interferon-beta in the treatment of multiple sclerosis. Derwenskus J, Lublin FD. Adv Neurol; 2006 Nov 08; 98():257-71. PubMed ID: 16400838 [No Abstract] [Full Text] [Related]
6. Glatiramer and suspected multiple sclerosis. No proven advantage. Prescrire Int; 2010 Aug 08; 19(108):160. PubMed ID: 20941852 [No Abstract] [Full Text] [Related]
7. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Tan H, Cai Q, Agarwal S, Stephenson JJ, Kamat S. Adv Ther; 2011 Jan 08; 28(1):51-61. PubMed ID: 21153000 [Abstract] [Full Text] [Related]
11. 'Time is brain' also in multiple sclerosis. Freedman MS. Mult Scler; 2009 Oct 08; 15(10):1133-4. PubMed ID: 19808740 [No Abstract] [Full Text] [Related]
12. Multiple sclerosis: monotherapy rules. Hauser SL, Josephson SA, Johnston SC. Ann Neurol; 2013 Mar 08; 73(3):A5-6. PubMed ID: 23596013 [No Abstract] [Full Text] [Related]
13. [Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)]. Federal service on surveillance in healthcare and social development (Roszdravnadzor). Zh Nevrol Psikhiatr Im S S Korsakova; 2011 Mar 08; 111(2 Pt 2):93-8. PubMed ID: 21916163 [No Abstract] [Full Text] [Related]
14. A practical approach to immunomodulatory therapy for multiple sclerosis. Burks JS. Phys Med Rehabil Clin N Am; 2005 May 08; 16(2):449-66, ix. PubMed ID: 15893681 [Abstract] [Full Text] [Related]
15. [Early immunotherapy in MS reduces the risk of later disability. The secondary progressive course is delayed, according to a study with virtual placebo]. Tedeholm H, Skoog B, Hillert J, Runmarker B, Stawiarz L, Oluf A. Lakartidningen; 2005 May 08; 104(22):1684-8. PubMed ID: 17601317 [No Abstract] [Full Text] [Related]
16. Corticosteroids in combination therapy for multiple sclerosis. Cohen JA. Lancet Neurol; 2009 Jun 08; 8(6):502-3. PubMed ID: 19409855 [No Abstract] [Full Text] [Related]
17. Interferon-beta for multiple sclerosis: Long-term benefits? Rudick RA, Cutter G. Ann Neurol; 2007 Apr 08; 61(4):283-5. PubMed ID: 17444503 [No Abstract] [Full Text] [Related]
18. Combination therapy for treatment of multiple sclerosis. Lublin FD, Reingold SC. Ann Neurol; 1998 Jul 08; 44(1):7-9. PubMed ID: 9667587 [No Abstract] [Full Text] [Related]
19. A practical guide to pediatric multiple sclerosis. Huppke P, Gärtner J. Neuropediatrics; 2010 Aug 08; 41(4):157-62. PubMed ID: 21086219 [Abstract] [Full Text] [Related]
20. Interferon beta in multiple sclerosis: how much BENEFIT? Pittock SJ. Lancet; 2007 Aug 04; 370(9585):363-4. PubMed ID: 17678997 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]